CIPLA Share Price Analysis April 2026
Cipla Limited
India’s Respiratory & Generic Pharma Champion — Navigating a Leadership Transition
Cipla Limited, incorporated in 1935, is India’s third-largest pharmaceutical company by domestic prescription market share. The company operates through two segments — Pharmaceuticals (96.9% of revenues) and New Ventures — across India (39.4% of revenue), the United States (18.5%), South Africa (17%), and Rest of World (25.1%).
Cipla holds a commanding #1 position in Respiratory therapy in India, is #3 overall in the domestic Rx market, and is among the fastest-growing generic players in North America. Its 7,500+ field force reaches ~85% of Indian physicians. The chronic therapies mix (respiratory, cardiology, oncology, diabetes) now constitutes ~61% of India revenue, providing durable, sticky revenue streams.
A pivotal leadership transition took effect on 1 April 2026 — Achin Gupta assumed the role of MD & Global CEO, succeeding Umang Vohra who led the company through a 28.7% PAT CAGR over five years. Near-term catalysts include gAbraxane (Goa facility cleared by USFDA with VAI status), the Yurpeak® tirzepatide partnership with Eli Lilly, and a pipeline of seven products targeted for launch by FY27.
| Metric (₹ Cr) | FY23A | FY24A | FY25A | FY26E | FY27E |
|---|---|---|---|---|---|
| Revenue | 22,753 | 25,774 | 27,337 | 30,205 | 31,309 |
| Revenue Growth (%) | 4.5% | 13.3% | 6.1% | 10.5% | 3.7% |
| EBITDA | 5,027 | 6,291 | 7,366 | 7,531 | 7,380 |
| EBITDA Margin (%) | 22.1% | 24.4% | 26.9% | 24.9% | 23.6% |
| Adj. PAT | 3,017 | 4,262 | 4,813 | 5,250 | 4,935 |
| Diluted EPS (₹) | 37.4 | 52.8 | 59.6 | 65.0 | 61.1 |
| EPS Growth (%) | — | 41.2% | 12.9% | 9.1% | -6.0% |
| P/E at CMP (₹1,176) | 31.5x | 22.3x | 19.7x | 18.1x | 19.2x |
India Business: Growing at 8–10% YoY. Chronic therapies (respiratory, cardiology, diabetes) now form 61% of India revenue and continue to outpace IPM growth. 1,500 new MRs added for chronic therapies. Digital Breathe Free platform has 5 lakh+ downloads. India remains the most durable growth engine.
US Business: Albuterol inhaler market share gains underpin near-term performance. gAbraxane launch (cleared, post-VAI at Goa) expected H2 FY26 — potential $100–150M peak sales opportunity. gAdvair and gSymbicort remain FY27 events. US growth moderates sharply in FY27 due to Lenalidomide (GRevlimid) revenue halving.
South Africa / EM: South Africa surged 33.5% YoY in Q4 FY25, driven by tender wins. Lanreotide supply normalisation from Q1 FY26 adds back EM momentum. Cipla is the 3rd largest player in the SAGA private market.
New Ventures: Biosimilars, oligonucleotides, peptides, and consumer healthcare represent medium-term optionality. Tirzepatide (Yurpeak®) for obesity via Eli Lilly partnership is a transformative call option.
EPS trajectory: FY26E EPS of ₹65 is achievable (+9% YoY). FY27E faces ~6% headwind from Lenalidomide cliff, but a successful gAdvair launch could partially offset this. Net cash position and debt-free balance sheet provide capacity for buybacks or inorganic growth.
| Company | CMP (₹) | Mkt Cap (Cr) | P/E (TTM) | ROE (%) | Revenue (Cr) | 5yr PAT CAGR | Rating |
|---|---|---|---|---|---|---|---|
| Cipla | 1,176 | 96,320 | 17.5x | 17.7% | 27,337 | 28.7% | Accumulate |
| Sun Pharma | ~1,600 | ~3,84,000 | ~28x | ~18% | ~54,000 | ~22% | Market Perform |
| Dr. Reddy’s | ~1,180 | ~98,000 | ~18x | ~19% | ~31,000 | ~30% | Neutral |
| Lupin | ~1,950 | ~88,000 | ~26x | ~16% | ~22,000 | ~35% | Neutral |
| Aurobindo Pharma | ~1,100 | ~64,000 | ~16x | ~13% | ~30,000 | ~12% | Underperform |
| Sector Avg. | — | — | ~22x | ~17% | — | ~25% | — |
